Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) has announced it will release its fourth quarter and full year 2024 financial results and business update after market close on February 26, 2025. The company will host a conference call and simultaneous webcast at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on the same day.

Interested participants can pre-register for the telephone conference call through the provided link. The webcast will be accessible through Theravance Biopharma's website under the Investors section, Events and Presentations. A replay of the webcast will remain available on the company's website for 30 days until March 28, 2025.

DUBLIN, Ireland, Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 28, 2025.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-26-2025-302374229.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma (TBPH) report Q4 and full year 2024 earnings?

Theravance Biopharma will report its Q4 and full year 2024 financial results after market close on Wednesday, February 26, 2025.

What time is TBPH's Q4 2024 earnings conference call?

The earnings conference call is scheduled for 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on February 26, 2025.

How long will TBPH's Q4 2024 earnings webcast replay be available?

The webcast replay will be available on Theravance Biopharma's website for 30 days through March 28, 2025.

Where can I access TBPH's Q4 2024 earnings webcast?

The webcast can be accessed through Theravance Biopharma's website (www.theravance.com) under the Investors section, Events and Presentations.